Abstracts tagged "treatment"

Abstract Number: 574 • 2018 ACR/ARHP Annual Meeting
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Roy Fleischmann¹, Mark C. Genovese², Anabela Cardoso³, Luna Sun³, Yun-Fei Chen³, Chad D. Walls³, Douglas E. Schlichting³, Tsutomu Takeuchi⁴, Maxime Dougados⁵, Josef S. Smolen⁶ and Jeffrey R. Curtis⁷, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keio University School of Medicine, Tokyo, Japan, ⁵Paris Descartes University, Hôpital Cochin, Paris, France, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor, has shown clinical efficacy in patients (pts) with RA and an inadequate response to conventional…
Abstract Number: 2551 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Mark C. Genovese², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁶, Rebecca Kunder¹⁵, Di An¹⁷, Luc Meuleners¹⁸, Robin Besuyen¹⁸, Rieke Alten¹⁹ and René Westhovens²⁰, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Stanford University Medical Center, Palo Alto, CA, ³Oregon Health and Science University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Cons. Priv. Temuco, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Kft, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³Qualiclinic Kft., Budapest, Hungary, ¹⁴AMED Medical Center, Warsaw, Poland, ¹⁵Gilead Sciences, Inc., Foster City, CA, ¹⁶Gilead Sciences, Inc, Foster City, CA, ¹⁷Gilead Science, Inc., Foster City, CA, ¹⁸Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ¹⁹Schlosspark-Klinik University Medicine, Berlin, Germany, ²⁰Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: The orally administered, selective inhibitor of Janus Kinase 1 (JAK1), filgotinib (FIL), is currently being investigated for the treatment of rheumatoid arthritis (RA) in…
Abstract Number: 575 • 2018 ACR/ARHP Annual Meeting
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Elliot Hepworth², Reza Mirza², Angela Cesta³, Maggie Larche⁴ and Claire Bombardier^1,5,6, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ³Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁴Medicine, McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) may discontinue their biologic disease modifying antirheumatic drug (bDMARDs) due to non-response, loss of response or adverse events. However,…
Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Guillaume Decarriere¹, Thomas Barnetche², Cédric Lukas³, Cécile Gaujoux-Viala⁴, Bernard Combe⁵, Jacques Morel⁶ and Claire I. Daien⁷, ¹Department of Rheumatology, CHU Lapeyronie, Montpellier, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…
Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Nancy A. Shadick¹, Michael E Weinblatt¹, Christine K Iannaccone², Michelle Frits³, Tigwa Davis⁴, Christopher Young⁴, David H. Collier⁵, Mahdi Gharaibeh⁵ and Bradley S. Stolshek⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Health Analytics, LLC, Columbia, MD, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…
Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Andreas Kerschbaumer¹, Harald Herkner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department for Emergency Medicine, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…
Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan
Song-Chou Hsieh¹, Yi-Hsing Chen², Wei-Sheng Chen³, Wen-Chan Tsai⁴, Jui-Chieh Hu⁵, Hsiang-Cheng Chen⁶, Jack Mardekian⁷ and Chacun Lai⁸, ¹National Taiwan University Hospital, Taipei, Taiwan, ²Taichung Veterans General Hospital, Taichung City, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, ⁷Pfizer Global Biometrics & Data Management, NY, NY, ⁸Pfizer PFE Limited, New Taipei, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
Abstract Number: 2966 • 2018 ACR/ARHP Annual Meeting
Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Hilde B Hammer¹, Lars Fritjof Karoliussen², Lene Terslev³, Espen A. Haavardsholm¹, Tore Kvien⁴ and Till Uhlig⁵, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark, ⁴RAID working group for EULAR, Zurich, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Uric monosodium urate (MSU) depositions are detected by ultrasound (US), and US is included in the ACR/EULAR classification criteria for gout. OMERACT definitions for…
Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Caitrin Coffey¹, Michael Richter¹, Cynthia S. Crowson², Matthew J. Koster³, Kenneth J. Warrington⁴ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
Abstract Number: 395 • 2017 ACR/ARHP Annual Meeting
Pharmacological and Safety Profiles of Cyclin-Dependent Kinase 4/6 Inhibitor, Candidate for Development As Rheumatoid Arthritis Therapeutic Option
Johji Nomura¹, Shunsuke Tsujimoto², Kei Tamura², Wataru Yamamoto², Hiroshi Takahashi², Kyohei Horie², Toshiya Mashiko², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the excessive proliferation of synovial…
Abstract Number: 2292 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Common Treatment Strategies for Juvenile Arthritis in Usual Practice: Results from the Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort
Amieleena Chhabra¹, Adam Huber^2,3, Natalie J. Shiff⁴, Gilles Boire⁵, Kiem Oen⁶ and Jaime Guzman¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²IWK Health Centre, Halifax, NS, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University of Florida, Gainesville, FL, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Pediatrics and Child Health University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The efficacy of medications in randomized trials may differ substantially from their effectiveness (degree of beneficial effect under “real world” clinical settings). Reliable estimates…
Abstract Number: 451 • 2017 ACR/ARHP Annual Meeting
A Matrix Risk Model for Prediction of Radiographic Progression in Early Rheumatoid Arthritis Based on Treatment Response at 3 Months
Pooneh S. Akhavan¹, Daming Li¹, Sahar Tabatabvakili¹ and Edward C. Keystone², ¹Mount Sinai Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada
Background/Purpose: The present study aimed to develop a matix to predict risk of radiographic progression in patients with early rheumatoid arthritis. The focus of this…
Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Regina Kurrasch⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Keio University School of Medicine, Tokyo, Japan, ³University of Toronto, Newmarket, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…
Abstract Number: 498 • 2017 ACR/ARHP Annual Meeting
Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients
Carlos Fernández-Díaz¹, Santos Castañeda², Clara Ojeda-Garcia³, Alejandro Olivé⁴, Patricia Carreira⁵, Trinidad Perez Sandoval⁶, Miriam Retuerto Guerrero⁷, Evelin Cecilia Cervantes Pérez⁸, Samantha Rodriguez⁹, Bryan Josue Robles Flores¹⁰, Blanca Hernández-Cruz¹¹, Ana Urruticoechea-Arana¹², Olga Maiz¹³, Desiree Palma¹⁴, Luis Arboleya¹⁵, Gema Bonilla¹⁶, Manuel Rodríguez-Gómez¹⁷, Concepción Delgado¹⁸, Rosa Expósito¹⁹, Ana Ruibal Escribano²⁰, Juan Blanco Madrigal²¹, José Antonio Bernal²², Paloma Vela²³, Belen Alvarez-Rodriguez²⁴, María Concepción Fito Manteca²⁵, Javier Narváez²⁶, Manuel Jose Moreno²⁷, Mireia López-Corbeto²⁸, Natalia Mena-Vazquez²⁹, S. Romero-Yuste³⁰, Clara Aguilera-Cros³¹, Sergi Ordoñez³², Ignacio Villa-Blanco³³, Nuria Vegas-Revenga¹, Victor Mora-Cuesta³⁴, Javier Loricera¹, Miguel Angel González-Gay¹, José Luis Hernandez³⁵ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ⁴Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁵Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Rheumatology, Hospital de León, LEÓN, Spain, ⁷Rheumatology, Hospital de León, Leon, Spain, ⁸Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, ⁹H. German Trias., Barcelona, Spain, ¹⁰Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹²Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹³Hospital Donostia. Spain, San Sebastian, Spain, ¹⁴Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ¹⁵Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain, ¹⁷Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ¹⁸H. Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²⁰Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ²¹Rheumatology, Hospital de Basurto, BIlbao, Spain, ²²Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ²³Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ²⁴Hospital Txagorritxu, Vittoria, Spain, ²⁵Reumatología, Hospital de Navarra, Pamplona, Spain, ²⁶Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²⁷Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, ²⁸Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²⁹Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, ³⁰H. Pontevedra, Pontevedra, Spain, ³¹Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, ³²Hospital Universitario Arnau de Vilanova, Vilanova, Spain, ³³Hospital de Sierrallana, Sierrallana, Spain, ³⁴Neumology, Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain, ³⁵Division of Internal Medicine., Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain
Background/Purpose: Disease modifying antirheumatic drugs (DMARD) such as methotrexate (MTX), ) or antiTNFα have been implicated in exacerbation of Interstitial lung disease (ILD)of rheumatoid arthritis…
Abstract Number: 2472 • 2017 ACR/ARHP Annual Meeting
Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Daniel Aletaha¹, Carter Thorne², Michael Schiff³, Masayoshi Harigai⁴, Prasheen Agarwal⁵, Ravi Rao⁶, Christopher Cohen⁷, Ben Cheng⁵, Kurt Brown⁷ and Benjamin Hsu⁵, ¹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²University of Toronto, Newmarket, ON, Canada, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ⁷GlaxoSmithKline, Collegeville, PA
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, is in development for rheumatoid arthritis (RA) in…

« Previous Page
1
…
6
7
8
9
10
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].